FIELD: biotechnology.
SUBSTANCE: method of obtaining a labeled polypeptide, a labeled polypeptide for its visualization, and a method of determining at least the internalization and/or intracellular transport of the labeled polypeptide are proposed. A polypeptide containing an acceptor site for sortase or a donor site for sortase, a non-cytotoxic protease containing the L-chain of clostridial neurotoxin, or its proteolytically inactive mutant, a targeting part (TP) that is capable of binding to a binding site on a target cell, and a translocation domain are obtained. The polypeptide is incubated with sortase and a labeled substrate containing a sortase donor site or an acceptor site for sortase, respectively, and a conjugated detectable label. A labeled polypeptide that does not have reduced potency compared to the equivalent unlabeled polypeptide and/or exhibits similar cell binding, translocation, and cleavage of the SNARE protein to the equivalent unlabeled polypeptid are obtained.
EFFECT: visualization of cell binding, translocation and/or cleavage of the SNARE protein using a cell-based assay or in vivo.
15 cl, 6 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
FUSION PROTEINS AND METHODS OF TREATMENT, PREVENTION OR ALLEVIATION OF PAIN | 2013 |
|
RU2652954C2 |
SUPPRESSION OF ALLODYNIA INDUCED BY BONE CANCER | 2019 |
|
RU2791640C2 |
RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
METHODS OF INCREASING SPECIFIC PINCH OF BOTULINUM NEUROTOXIN BY CELLS | 2016 |
|
RU2684404C2 |
NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
SYSTEM FOR DETECTING FULL-LENGTH AND PARTIALLY TRUNCATED TYPE A NEUROTOXIN | 2010 |
|
RU2545825C9 |
Authors
Dates
2023-08-02—Published
2020-01-16—Filed